title: Reduction of beta-adrenergic receptors by tertatolol: an additional mechanism for beta-adrenergic blockade.
abstract: Tertatolol is a potent new beta-blocker with no intrinsic sympathomimetic activity or beta 1/beta 2-receptor subtype selectivity. When given at therapeutic doses (5 mg/day) to human subjects it induced a reduction in the beta-adrenergic receptor number measured by 3H-CGP 12177 specific binding, without any change in the affinity on intact lymphocytes. This reduction was seen 7 hours (54%), 24 hours (35%), and 48 hours (30%) after a single drug dose. A similar receptor reduction was observed 7 hours (42%), 24 hours (37%), and 48 hours (15%) after 14 doses of the drug. In parallel, the pharmacologic efficacy of the drug was evident from the reduction in supine and upright heart rates and after submaximal exercise; heart rate was reduced to the same extent after single or repeated drug doses. The reduction of receptor number correlated well with the reduction in heart rate in the supine (P less than 0.001) and upright (P less than 0.01) positions and after exercise (P less than 0.02). In in vitro competitive binding experiments tertatolol was found to be a competitive inhibitor of beta-adrenergic receptors. However, on intact human lymphocytes preincubated with this drug, tertatolol reduced the density of beta-adrenergic receptors. We conclude that tertatolol, besides competitively inhibiting beta-adrenergic receptors, induced a marked and lasting decrease in the beta-adrenergic receptor number. This effect may be important for its beta-blocking effects.
authors.forename: A
authors.initials: A
authors.lastname: De Blasi
authors.forename: M
authors.initials: M
authors.lastname: Lipartiti
authors.forename: F
authors.initials: F
authors.lastname: Pirone
authors.forename: C
authors.initials: C
authors.lastname: Rochat
authors.forename: J F
authors.initials: JF
authors.lastname: Prost
authors.forename: S
authors.initials: S
authors.lastname: Garattini
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D004341:Drug Evaluation; D004347:Drug Interactions; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D005082:Physical Exertion; D011412:Propanolamines / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000378:metabolism; D013876:Thiophenes
chemical_list: D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; D013876:Thiophenes; C005632:tertatolol; C033394:CGP 12177